Alongside promising first HAE data, Intellia posts readout in Regeneron-partnered ATTR program
In August, Alnylam touted a Phase III success for transthyretin amyloidosis, or ATTR for short, with cardiomyopathy — a disease that causes protein buildup in the heart, so it can’t pump at full capacity. However, Intellia and Regeneron are here to compete, with a therapy that only needs to be dosed once.
In today’s update on part 1 of the study, Intellia said that its therapy, known as NTLA-2001, reduced mean serum transthyretin (the protein that builds up in the heart) by 93% and 92% in patients who got either a 0.7 mg/kg or 1.0 mg/kg dose of the therapy, respectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
